Cantitate/Preț
Produs

Systemic Treatment of Prostate Cancer: Oxford Oncology Library

Editat de Alan Horwich
en Limba Engleză Paperback – 11 feb 2010
Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple
sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay of endocrine therapy in this group of patients, though anti-androgens, oestrogens, and corticosteroids can also
cause remissions. In recent years effective and well-tolerated chemotherapy regimens have been developed and evaluated. Docetaxel has an established role, and a range of biologically-targeted agents are in development.

The dominant pattern of metastatic spread is to the axial skeleton and most symptomatic care is directed to palliation of bone pain. The role of bisphosphonates remains controversial, but bone-directed isotopes such as Strontium-89 are effective.

Part of the Oxford Oncology Library, this pocketbook summarizes the up-to-date information on the use of systemic therapies in the management of prostate cancer (early stage, metastatic disease, and treatment of biochemical recurrence). With contributions from leading oncologists from both Europe
and the USA, the book provides a practical guide to the range of endocrine and cytotoxic therapies currently available to clinicians, as well as to other palliative anticancer strategies, and will be valuable to all health professionals involved in the management of patients with prostate cancer.

Citește tot Restrânge

Din seria Oxford Oncology Library

Preț: 17200 lei

Preț vechi: 18105 lei
-5%

Puncte Express: 258

Preț estimativ în valută:
3295 3569$ 2826£

Cartea nu se mai tipărește

Doresc să fiu notificat când acest titlu va fi disponibil:

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780199561421
ISBN-10: 0199561427
Pagini: 104
Ilustrații: 2 line drawings
Dimensiuni: 100 x 180 x 5 mm
Greutate: 0.09 kg
Editura: Oxford University Press
Colecția OUP Oxford
Seria Oxford Oncology Library

Locul publicării:Oxford, United Kingdom

Descriere

Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long beenthe mainstay of endocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroids can also cause remissions. In recent years effective and well-tolerated chemotherapy regimens have been developed and evaluated. Docetaxel has an established role, and a range ofbiologically-targeted agents are in development.The dominant pattern of metastatic spread is to the axial skeleton and most symptomatic care is directed to palliation of bone pain. The role of bisphosphonates remains controversial, but bone-directed isotopes such as Strontium-89 are effective.Part of the Oxford Oncology Library, this pocketbook summarises the up-to-date information on the use of systemic therapies in the management of prostate cancer (early stage, metastatic disease, and treatment of "biochemical" recurrence). With contributions from leading oncologists from both Europe and the USA, the book provides a practical guide to the range of endocrine and cytotoxic therapies currently available to clinicians, as well as to other palliative anticancer strategies, and will bevaluable to all health professionals involved in the management of patients with prostate cancer.

Notă biografică

Alan Horwich is Professor of Oncology at the Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK.